期刊文献+

HPLC法测定托拉塞米口服制剂的含量

Determination of Torasemide in Torasemide Oral Preparation by HPLC
下载PDF
导出
摘要 目的:建立高效液相色谱法测定托拉塞米片剂和胶囊中托拉塞米的含量的方法。方法采用 Phenomenex Luna C18(250mm×4.6mm,5μm)色谱柱,以0.1%三乙胺(用磷酸调节pH至3.5)-甲醇(55∶45)为流动相,流速为1.0mL·min -1,检测波长为291nm。结果托拉塞米在20.06~401.16μg· mL -1范围内浓度与峰面积呈良好的线性关系(r=0.9999),片剂平均回收率为99.90%,RSD为0.52%(n=9);胶囊平均回收率为100.26%,RSD为0.34%(n=9)。结论本方法简便、快速,结果准确,重现性较好。 OBJECTIVE To establish a method for determination content of Torasemide in Torasemide Tablet and Torasemide Capsules by HPLC.METHODS Phenomenex Luna C18(250mm ×4.6mm,5μm)column was used and 0.1%Triethylamine-methanol (55∶45) was used as mobil phase ,the flow rate was 1.0mL·min -1 ,the detecting wavelength was at 291 nm.RESULTS There was a good linear relationship between the concentration of to-rasemide and peak area within a range of 20.06-401.16μg· mL-1 ( r=0.9999 ).The average recover of tablet was 99.90%,with RSD=0.52%( n=9 );The average recover of capsule was 100.26%, with RSD=0.34%( n=9 ).CONCLUSION The method is simple ,highly repeatable and accurate.
出处 《海峡药学》 2014年第5期27-31,共5页 Strait Pharmaceutical Journal
关键词 含量测定 托拉塞米 高效液相色谱法 Content Torasemide HPLC
  • 相关文献

参考文献6

二级参考文献27

  • 1[1][1] Blose JS,Adams KF Jr,Patterson JH. Torsemide:a pyridine-sulfonylurea loop diuretic[J]. Ann Pharmacother, 1995,29(4): 396 - 402.
  • 2[2]Brater DC. Clinical pharmacology of loop diuretics [J]. Drugs,1991,41 (Suppl 3) :S14 - S22.
  • 3[3]Frieder HA,Buckley MM-T. Torasemide-a review of its pharmacology, properties and therapeutic potential [J]. Drugs, 1991,41(1) :S81 - S103.
  • 4[4]Bart WH,Smith HL,Karnes HT,et al.Torasemide dose proportionality of pharmacokinetics and pharmacodynamics [J]. Prog Pharmacol Clin Pharmacol, 1990,8: 29 - 37.
  • 5[5]Fowler SF, Murray KM. Torsemide: A new loop diruetic [J].Am J Health-Syst Pharm, 1995,52(15): 1771 - 1780.
  • 6[6]Knauf H,Spahn H,Mutschler E. The loop diuretic torasemide in chronic renal failure: pharmacokinetics and pharmacodynamics [J]. Drugs, 1991,41 (Suppl 3) :S23 - S34.
  • 7[7]Kido H,Ohtaki Y. Torasemide (LUPRAC) :a review of its pharmacological and clinical profile[J]. Nippon Yakeurigaku Zasshi,2001,118(2):97- 105.
  • 8[8]Kruck F. Acute and long term effects of loop diuretics in heart failure[J]. Drugs, 1991,41 (Suppl 3): S60 - S68.
  • 9[9]Barr WH,Smith HL,Karnes HT,et al. Comparison of bioavailability, pharmacokinetics and pharmacodynamics of torasemide in young and elderly healthy volunteers[J]. Prog Pharmacol Clin Pharmmol, 1990 ;8:15 - 28.
  • 10[10]Schwartz S,Brater DC,Pound D,et al. Bioavailability,pharmacokinetics and pharmacodynamics of torasemide in patients with cirrhosis[J]. Clin Pharmacol Ther, 1993,54(1): 90 - 97.

共引文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部